Natera, Inc. ($NTRA) Stock Forecast: Down 8.9% Today

What is Natera, Inc.?

Natera Inc. (NASDAQ: NTRA) is a company specializing in genetic testing and diagnostic services, particularly focusing on cancer detection and treatment guidance. The stock saw a decline in value today following developments in its diagnostic testing products and analyst outlook.

Why is Natera, Inc. going down?

NTRA stock is down 8.9% on Feb 4, 2026 18:16

• The decrease in Natera Inc. (NTRA) stock value may be due to a combination of strong revenue performance but a miss in earnings per share, as well as recent insider selling.
• Concerns around regulatory approval timelines and market potential arose following the FDA premarket approval application for Natera's Signatera CDx test in muscle-invasive bladder cancer (MIBC).
• Despite analyst optimism with a "Moderate Buy" rating and a high target price, the surge in institutional ownership and insider selling likely led to short-term selling pressure, contributing to the bearish market trend.

NTRA Price Chart

NTRA Technical Analysis

NTRA News

Trading Systems Reacting to (NTRA) Volatility

This article analyzes Natera Inc. (NASDAQ: NTRA) volatility using AI-driven trading systems, highlighting weak near-term sentiment despite long-term strength. It presents various trading strategies—position, momentum breakout, and risk hedging—along with multi-timeframe signal analysis, including support and resistance levels. The report emphasizes a significant 39.5:1 risk-reward setup targeting an 11.5% gain.

https://news.stocktradersdaily.com/news_release/17/Trading_Systems_Reacting_to_NTRA_Volatility_020426083202_1770211922.html

Natera Files FDA PMA for Signatera CDx in Muscle-Invasive Bladder Cancer

Natera has submitted a Premarket Approval (PMA) application to the U.S. FDA for its Signatera CDx test to detect molecular residual disease (MRD) in muscle-invasive bladder cancer (MIBC) patients. This application aims to identify patients who could benefit from atezolizumab (Tecentriq®) and is supported by data from the randomized, double-blind phase 3 IMvigor011 trial. If approved, Signatera CDx would be a first-in-class companion diagnostic MRD test for bladder cancer, moving MRD-guided treatment into a formal FDA-approved pathway.

https://oncodaily.com/techology/signatera-cdx450856

FDA premarket approval sought for Signatera CDx test in MIBC

Natera has submitted an application to the FDA for premarket approval of its Signatera CDx test as a companion diagnostic for selecting muscle-invasive bladder cancer (MIBC) patients for adjuvant atezolizumab treatment. This application is supported by phase 3 IMvigor011 trial data, which demonstrated that circulating tumor DNA (ctDNA) can predict which patients benefit from atezolizumab, showing significant improvements in disease-free and overall survival for ctDNA-positive patients. The findings also suggest that ctDNA-negative patients may safely avoid adjuvant treatment.

https://www.urologytimes.com/view/fda-premarket-approval-sought-for-signatera-cdx-test-in-mibc

Natera, Inc. (NASDAQ:NTRA) Receives Average Rating of "Moderate Buy" from Analysts

Eighteen analysts have given Natera, Inc. (NASDAQ:NTRA) a consensus "Moderate Buy" rating with an average 12-month target price of $249.20. While the company exceeded revenue estimates, it missed on EPS, and insider selling has been noted. Natera recently completed enrollment in a key transplant trial.

https://www.marketbeat.com/instant-alerts/natera-inc-nasdaqntra-receives-average-rating-of-moderate-buy-from-analysts-2026-02-02/

Natera, Inc. $NTRA Shares Purchased by New York State Common Retirement Fund

The New York State Common Retirement Fund significantly increased its stake in Natera, Inc. ($NTRA) by 63.2% in Q3, now holding 148,247 shares worth about $23.86 million. Institutional ownership of Natera remains high at 99.9%, with major investors like Vanguard and JPMorgan also increasing their positions. However, company insiders have been net sellers, disposing of over half a million shares valued at nearly $115 million in the last quarter, which could create short-term selling pressure.

https://www.marketbeat.com/instant-alerts/filing-natera-inc-ntra-shares-purchased-by-new-york-state-common-retirement-fund-2026-02-01/

Trending Today

O'Reilly Automotive Inc. ($ORLY) Stock Forecast: Down 5.8% Today

Advanced Micro Devices Inc. ($AMD) Stock Forecast: Down 5.1% Today

Wix.com Ltd. ($WIX) Stock Forecast: Down 5.2% Today

Ralph Lauren Corporation ($RL) Stock Forecast: Down 5.0% Today

Verisk Analytics Inc. ($VRSK) Stock Forecast: Down 5.0% Today

KKR & Co. Inc. Class A ($KKR) Stock Forecast: Down 5.2% Today

Bitcoin ($BTC) Crypto Forecast: Down 11.0% Today

S&P Global Inc. ($SPGI) Stock Forecast: Down 4.0% Today

Eli Lilly and Company ($LLY) Stock Forecast: Down 5.8% Today

Huntington Ingalls Industries Inc. ($HII) Stock Forecast: Down 12.1% Today

Natera, Inc. Price History

08.07.2025 - NTRA Stock was up 16.5%

• Natera (NTRA) reported a Q2 loss but surpassed revenue estimates, indicating strong top-line growth.
• The positive revenue surprise likely boosted investor confidence in the company's long-term growth prospects.
• Investors may be optimistic about Natera's future potential in the genetic testing market, driving the bullish movement in the stock.
• The market may be interpreting the revenue beat as a sign of Natera's ability to capitalize on the growing demand for personalized healthcare solutions, leading to the bullish momentum in the stock.

04.01.2026 - NTRA Stock was down 8.9%

• The decrease in Natera Inc. (NTRA) stock value may be due to a combination of strong revenue performance but a miss in earnings per share, as well as recent insider selling.
• Concerns around regulatory approval timelines and market potential arose following the FDA premarket approval application for Natera's Signatera CDx test in muscle-invasive bladder cancer (MIBC).
• Despite analyst optimism with a "Moderate Buy" rating and a high target price, the surge in institutional ownership and insider selling likely led to short-term selling pressure, contributing to the bearish market trend.

04.01.2026 - NTRA Stock was down 7.7%

• The decline in Natera's stock today may be influenced by various factors:
• Positive developments, such as the FDA PMA application for the Signatera CDx test for bladder cancer, were overshadowed by concerns related to the company's financial performance. Natera fell short on EPS, and significant insider selling took place, amounting to over $114 million in the previous quarter.
• The substantial insider selling likely created selling pressure on the stock in the short term.
• Despite increased stakes by institutional investors like the New York State Common Retirement Fund and Mirae Asset Global Investments Co. Ltd., the notable insider selling and earnings miss could have affected overall investor sentiment.
• While the decrease in short interest in January suggested a decline in bearish sentiment, today's market movement implies that other factors impacted the stock more significantly.

08.00.2026 - NTRA Stock was down 5.4%

• Despite recently reaching an all-time high, Natera Inc. (NTRA) experienced a bearish market movement today, possibly due to concerns raised about the stock's valuation compared to its Fair Value.
• The company's financial outlook, supported by positive developments such as the expanded Fetal Focus test and ALTAIR trial results, still harbors uncertainties regarding further reimbursement and guideline wins to counterbalance high expenses.
• The bearish movement may also be influenced by projections of negative net income for the year, despite increased price targets from various firms.
• Investors may be exercising caution regarding the stock's valuation and the company's capacity to convert clinical progress into sustainable financial growth, contributing to the observed bearish market movement today.

09.06.2025 - NTRA Stock was up 5.1%

• There was a strong bullish movement in Natera Inc. today.
• The rise in revenues and profits of a competitor in the AI tools and data services sector may have positively influenced market sentiment towards Natera Inc.
• Investors show optimism about Natera Inc.'s potential for revenue growth and improved margins, similar to the success seen by its competitor.
• The increasing adoption of AI technologies in the healthcare and biotechnology industries could be driving positive investor sentiment towards companies like Natera Inc.

06.00.2026 - NTRA Stock was up 6.3%

• The positive outcomes presented at the ASCO GI Symposium from its ALTAIR trial, showcasing significant disease-free survival benefits for colorectal cancer patients, likely contributed to Natera's bullish movement.
• Natera's stock price target was increased to $270 by Guggenheim, along with other analysts' optimistic adjustments, fueling investor confidence.
• The launch of the expanded 21-gene Fetal Focus single-gene non-invasive prenatal test further demonstrates Natera's commitment to innovation and product expansion, attracting more attention from investors.
• Strong revenue growth and positive market sentiment have driven the stock price upwards, overshadowing concerns such as insider selling and reduced stake by Calamos Advisors LLC.

12.00.2026 - NTRA Stock was down 5.5%

• The bearish movement in Natera's stock price today could be attributed to several factors:
• Despite Natera's strong preliminary fourth-quarter revenue and positive news surrounding its oncology tests, the market may have reacted negatively to President Moshkevich's significant stock sale, which could have raised concerns among investors.
• The collaboration with Exelixis on the STELLAR-316 trial for colorectal cancer patients, while promising in the long term, might have created uncertainty in the short term due to the expected initiation of the trial in mid-2026.
• The lack of specific details in the findings from the CALGB (Alliance)/SWOG 80702 study could have left investors wanting more clarity on the potential impact of the study results on Natera's products and services.
• Overall market conditions or sector-specific trends may have also played a role in the bearish movement of Natera's stock today, despite the positive developments highlighted in recent news.

22.00.2026 - NTRA Stock was up 5.1%

• Acquisition of a new position in Natera by Rakuten Investment Management Inc. reflects confidence in the company's future.
• Study results for Natera's colorectal cancer detection assay have been promising, showcasing the company's innovative technology and growth potential.
• Natera's publication of clinical validation for its tfMRD test in colorectal cancer reinforces its position as a leader in precision oncology.
• Selection of Natera's Fetal Focus sgNIPT for a prestigious presentation at the SMFM meeting underlines the company's advancements in genetic screening, likely contributing to positive market sentiment.

16.09.2025 - NTRA Stock was up 5.2%

• Natera has demonstrated impressive performance over the last 5 years, surpassing market performance by 5.63% annually, likely attracting investors seeking high returns.
• The company's emphasis on cutting-edge genetic testing technologies and its market capitalization of $23.35 billion have bolstered investor confidence and a positive market outlook.
• The favorable sentiment surrounding Natera's historical performance and growth prospects could have triggered heightened buying activity, resulting in today's notable bullish movement in the stock.

11.11.2025 - NTRA Stock was down 3.8%

• Insider selling, specifically by company directors and the CEO, could be a reason behind Natera's stock downturn, despite recent positive developments like the acquisition of Foresight Diagnostics and strong Q3 results.
• The acquisition of Foresight Diagnostics for up to $450 million may have raised investor concerns about integration challenges and potential value dilution.
• While institutional investors have significantly increased their positions and analysts have given positive ratings, ongoing insider selling, especially by top management, has created uncertainty and possibly triggered stock sell-offs.
• Despite optimistic analyst outlooks and robust revenue performance, continuous insider selling activities, including by key executives, might have unsettled investors and contributed to the bearish trend in Natera's stock today.

07.10.2025 - NTRA Stock was down 5.0%

• Natera exceeded revenue predictions but faced a notable loss in Q3 earnings, potentially influencing the stock's downturn.
• Worries about Natera's profitability outlook may have prompted investors to sell off the company's shares.
• The combination of uneven performance and a significant earnings shortfall could have eroded investor faith in Natera's future growth, triggering adverse market movements.

23.03.2025 - NTRA Stock was up 5.1%

• Demonstrating a remarkable performance over the last five years, surpassing the market by 19.34% annually, has attracted investors interested in high returns.
• With a focus on genetic testing and a market capitalization of $20.02 billion, Natera holds a prominent position within the biotech sector, instilling confidence in investors.
• The upward trend in NTRA's stock performance today may be linked to the ongoing positive outlook regarding the company's growth potential and market outperformance.